Earlier on Monday, FDA Accepted Takeda's Application Under Priority Review for Zasocitinib (TAK-279) For Moderate-To-Severe Plaque Psoriasis, With PDUFA Action Date in Q1 2027
Share
Why It Matters
Takeda's new skin medicine got fast-tracked by the FDA for review. The company will know if it's approved by spring 2027.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.